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ABSTRACT Combining antibiotics with potentiators that increase their activity is a
promising strategy to tackle infections caused by antibiotic-resistant bacteria. As po-
tentiators do not interfere with essential processes, it has been hypothesized that
they are less likely to induce resistance. However, evidence supporting this hypothe-
sis is lacking. In the present study, we investigated whether Burkholderia cenocepacia
J2315 bioﬁlms develop reduced susceptibility toward one such adjuvant, baicalin hy-
drate (BH). Bioﬁlms were repeatedly and intermittently treated with tobramycin
(TOB) alone or in combination with BH for 24 h. After treatment, the remaining cells
were quantiﬁed using plate counting. After 15 cycles, bioﬁlm cells were less suscep-
tible to TOB and TOBBH compared to the start population, and the potentiating
effect of BH toward TOB was lost. Whole-genome sequencing was performed to
probe which changes were involved in the reduced effect of BH, and mutations in
14 protein-coding genes were identiﬁed (including mutations in genes involved
in central metabolism and in BCAL0296, encoding an ABC transporter). No changes
in the MIC or MBC of TOB or changes in the number of persister cells were ob-
served. However, basal intracellular levels of reactive oxygen species (ROS) and ROS
levels found after treatment with TOB were markedly decreased in the evolved pop-
ulations. In addition, in evolved cultures with mutations in BCAL0296, a signiﬁcantly
reduced uptake of TOB was observed. Our results indicate that B. cenocepacia J2315
bioﬁlms rapidly lose susceptibility toward the antibiotic-potentiating activity of BH
and point to changes in central metabolism, reduced ROS production, and reduced
TOB uptake as mechanisms.
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Due to increasing levels of antimicrobial resistance, novel strategies to tacklebacterial infections are needed, and an interesting approach is the use of antibiotic
adjuvants or potentiators. Potentiators are compounds with little or no antibacterial
activity that interfere with bacterial resistance mechanisms and/or increase antimicro-
bial activity when coadministered with an antibiotic (1–5). A well-known class of
antibiotic adjuvants are quorum-sensing (QS) inhibitors (QSIs) (6). QSIs target the
cell-density-based bacterial communication network that regulates the expression of
multiple virulence factors (7, 8). Whether resistance would develop toward these
adjuvants is currently unknown, and QSIs have long been accepted as “evolution-
proof.” Indeed, since QSIs do not target pathways essential for growth, it has been
hypothesized that development of resistance would not occur (or at least would occur
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less frequently) due to the lack of selective pressure favoring the rise of resistant
mutants (9–13). However, natural selection occurs when heritable variation provides a
ﬁtness advantage and QS disruption can affect bacterial ﬁtness in conditions in which
a functional QS system is essential (8). This was, for example, shown by cultivating
Pseudomonas aeruginosa in medium with adenosine as a sole carbon source (14). As
growth on adenosine depends on the production of a nucleoside hydrolase, which is
positively regulated by the key QS signal receptor LasR, a functional QS system is
required for the growth of P. aeruginosa under these conditions (15). After addition of
the brominated furanone C-30 (a known QSI), growth of P. aeruginosa on adenosine
was impaired, resulting in selective pressure and the occurrence of resistant mutants.
Adding this QSI caused mutations in repressor genes of the multidrug resistance efﬂux
pump MexAB-OrpM, which resulted in an increased resistance toward C-30 (14). Also in
clinical P. aeruginosa isolates recovered from cystic ﬁbrosis (CF) patients never exposed
to C-30, mutations in these MexAB-OrpM repressor genes were found, leading to
reduced susceptibility to C-30 (14, 16). Based on these results, Maeda et al. speculated
that any strong selective pressure can induce resistance to antivirulence compounds
(14, 17). In clinical practice, these adjuvants would be coadministered with an antibiotic.
This means selective pressure imposed by this antibiotic needs to be included in the
experimental setup when investigating possible development of resistance toward the
adjuvants (1, 2). In addition, while most evolutionary studies on the development of
resistance are carried out with planktonic cells (18–20), 65 to 80% of all infections are
thought to be bioﬁlm related, and bioﬁlm-associated bacteria typically show a reduced
susceptibility toward antimicrobial agents (21).
Burkholderia cenocepacia is an opportunistic pathogen that causes severe lung
infections in people with CF, which can further develop into a life-threatening systemic
infection known as the cepacia syndrome (22). Antimicrobial therapy in CF often fails
due to the high innate resistance of B. cenocepacia toward many antibacterial agents
and high tolerance associated with its bioﬁlm lifestyle (22, 23). Previously, several
adjuvants were identiﬁed that increased the activity of tobramycin (TOB) (an aminogly-
coside antibiotic frequently used in CF lung infections) (24) toward B. cenocepacia
bioﬁlms, including the QSI baicalin hydrate (BH) (6, 25).
The goal of the present study is to evaluate whether (and how) B. cenocepacia J2315
bioﬁlm cells can lose susceptibility toward the TOB-potentiating activity of BH. To this
end, we used a slightly modiﬁed form of a previously described bead-based bioﬁlm
assay (26) in which B. cenocepacia J2315 cells were repeatedly and intermittently
exposed to TOB, TOBBH, or a control treatment (Fig. 1).
RESULTS AND DISCUSSION
Experimental evolution. Three lineages of B. cenocepacia J2315 cells were repeat-
edly and intermittently exposed to TOB (768 g/ml, which equals three times the MIC),
TOB (768 g/ml) plus BH (250 M) (TOBBH), or a control treatment (Fig. 1). After 24 h
of growth on the beads, Live/Dead staining was performed to evaluate bioﬁlm forma-
tion (see Fig. S1 in the supplemental material). A dense bioﬁlm was formed in the cavity
of the doughnut-shaped bead (rather than on the exterior sides of the bead) with
approximately 107 CFU/bead (prior to treatment).
The number of log(CFU/bead) after every cycle is shown in Fig. 2 and Table S1. After
ﬁtting a linear mixed-effect model (LMEM), using log(CFU/bead) as the dependent
variable and cycle, treatment, lineage, and their two- and three-way interactions as
ﬁxed effects, and plotting the residuals against the corresponding ﬁtted values, no
departures from the main assumptions of normality and constancy of error variance
were found. The remaining models were ﬁt for each lineage separately following
signiﬁcance of the three-way interaction effect, and residuals were assessed for each of
the models for each lineage. A detailed overview of the results of the statistical analysis
can be found in Table S2.
The results indicated that for all lineages, the interaction effect between treatment
and cycle was highly statistically signiﬁcant (P  0.001). A general observation within
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each lineage was the signiﬁcant difference in CFU recovered after TOB and the TOBBH
treatments compared to the control group (Table S2). The only exception was for
lineage 2, wherein at cycle 11 this difference was not statistically signiﬁcant (P 0.171).
Also, lineage 2 appeared to present more ﬂuctuations in number of surviving cells,
compared to lineages 1 and 3. At the start of the evolution experiment, the cells were
signiﬁcantly more susceptible to the TOBBH combination than to TOB alone, con-
ﬁrming that BH potentiates the activity of TOB against bioﬁlms, as previously shown (6,
27). Over time, bioﬁlm-grown B. cenocepacia J2315 cells became gradually less suscep-
tible to the treatment (both to treatment with TOB alone and to the TOBBH
combination treatment); this occurred in all three lineages (Fig. 2). The susceptibility to
TOBBH decreased faster than the susceptibility to TOB alone; differences in suscep-
tibility between TOBBH and TOB alone only persisted up to cycle 5, cycle 3, and cycle
4 for lineages 1, 2, and 3, respectively (Fig. S2 and Table S2).
Genome analysis. To investigate the reason behind this decreased susceptibility,
whole-genome sequencing was performed. The results are summarized in Table 1.
When considering all (nine) evolved lines, changes in 18 protein-coding genes were
observed, as well as a partial deletion of two larger regions. Some changes were
common and appeared in all evolved cultures at the same location (e.g., changes in
BCAL1315, BCAL1664, and BCAM0949); we speculate that these mutations were already
present in the starting population at low frequency and were enriched for during the
experimental evolution. Other changes occurred only in one or a few samples (e.g.,
mutations in BCAL0929, BCAL2476a, and BCAM1901) and likely arose during the
evolution study. For several genes that were mutated in multiple evolved cultures, we
noticed the occurrence of different types of mutations (e.g., BCAL0269, BCAL1525, and
BCAM0965).
All evolved cultures had mutations in the 5= untranslated region (5= UTR) of
BCAL1525 (either a single nucleotide polymorphism (SNP) or insertion of a transposase
at variable locations; Table 1). BCAL1525 encodes an Flp pilus assembly protein and has
a 307-nucleotide and strongly expressed 5= UTR with multiple transcription start sites
(TSS) (28). BCAL1525 to BCAL1536 seem to form an operon with Flp pilus genes,
although there is a terminator at positions 1690709 to 1690746 between BCAL1525 and
FIG 1 Experimental setup. Fresh inoculum is added to six cryobeads in the well of a 24-well microtiter plate. After
24 h, mature bioﬁlms (gray circles) are formed on the surfaces of the beads. These bioﬁlms are treated for 24 h.
Afterward, the supernatant is removed, and the beads are rinsed with PS. Two beads, containing a mature bioﬁlm,
are stored at –80°C. The four other beads are transferred to a Falcon tube, in which the sessile cells from the beads
are harvested. A part of these cells is used for quantiﬁcation, while another part is used for planktonic regrowth
of the cells (48 h).
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BCAL1526, and no further downstream TSS could be identiﬁed (28). Flp pili belong to
the type IVb pilus family (29), which is poorly characterized in Burkholderia species. In
P. aeruginosa type IV pili are thought to play a role in bioﬁlm formation (30), although
recent data suggest this may depend on the bioﬁlm model system used (31). Mutations
in BCAL1525 occur at high frequency in all evolved cultures, irrespective of the
treatment, suggesting that there is an evolutionary pressure to lose the pilus function
in the given experimental conditions. Since bioﬁlm formation is not affected in the
course of the experiment (Fig. 2), this indicates the Flp pilus is not required for bioﬁlm
formation under these conditions.
BCAL0296 encodes both the transmembrane and nucleotide binding domains of an
ABC transport protein, and it is the only gene which is mutated in all treated evolved
populations (except for one evolved population treated with TOB) but not in the
FIG 2 Numbers of B. cenocepacia J2315 bioﬁlm cells, expressed as log(CFU/bead), in the untreated
control (Control) and after repeated treatments with TOB or TOBBH. (Top) Lineage 1; (middle) lineage
2; (bottom) lineage 3.
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control evolved populations; three different types of mutations are observed in this
gene (a deletion, a nonsense mutation, and a nonsynonymous substitution; Table 1). In
the lineage that does not have mutations in BCAL0296 (TOB 3), we observed several
mutations that do not occur in other treated populations (i.e., in BCAL0736, BCAL2628,
and BCAM2284), but the function of these genes does not allow us to link them to the
reduced TOB susceptibility observed in bioﬁlms of this lineage.
Three mutated genes are related to central metabolism and occur in TOBBH-
treated lineages only. BCAL2631 and BCAM0965 are both involved in oxaloacetate
production. The mutation in BCAL2631 occurs only in one population exposed to
TOBBH; this gene encodes phosphoenol pyruvate kinase, which converts phosphoe-
nol pyruvate to oxaloacetate in the “reverse tricarboxylic acid (TCA) cycle.” Its activity
typically results in increased oxaloacetate levels and an increased ﬂux through the TCA
cycle (32). It was designated as conditionally essential in B. cenocepacia J2315 in a
minimal medium with only glucose as the substrate (33). BCAM0965 (encoding malate
dehydrogenase) is mutated in two out of three evolved populations exposed to
TOBBH. Just like phosphoenol pyruvate kinase, malate dehydrogenase (which con-
verts malate to oxaloacetate) activity will increase cellular oxaloacetate levels, likely
stimulating the TCA cycle. BCAM0965 is also conditionally essential in B. cenocepacia
J2315 (33). On top of that, in one TOBBH-exposed evolved population, a mutation in
a gene encoding the permease of a glucose/mannose ABC transporter (BCAL3040) was
observed, likely affecting the uptake of certain carbohydrates.
None of the mutations observed were located in genes known to be responsible for
aminoglycoside resistance, such as genes encoding aminoglycoside-modifying en-
zymes, efﬂux pumps, or ribosome methyltransferases, or in genes encoding ribosomal
RNAs (34, 35). Since mutations in these genes often come at the cost of reduced relative
growth ﬁtness (36), the regrowth phase between treatment cycles might have pre-
vented the accumulation of such mutations.
Role of QS and QSI. BH was previously described as a QSI (6), and in a recent study
we showed it also has QS-independent activities, including modulating the oxidative
stress response, that potentiate TOB in B. cenocepacia (27). To evaluate whether BH
directly inhibits the N-octanoyl-L-homoserine lactone synthase CepI (37, 38), an enzy-
matic assay with puriﬁed CepI was carried out. CepI enzymatic activity was ﬁrst tested
at the concentration of BH slightly below that used for the evolution study (200 M),
and at this concentration BH completely inhibits CepI. Subsequently, the 50% inhibitory
concentration (IC50) was determined (46.8 6.8 M), which conﬁrmed that BH inhibits
CepI in a concentration-dependent way (Fig. S3). The mutation in BCAM1870, coding
for CepI, is found in two evolved populations exposed to TOBBH and in a single
population exposed to TOB only; the same mutation (C131W) is found in these three
populations. In order to investigate the effect of the C131W mutation, we introduced
this mutation in wild-type CepI by site-directed mutagenesis and characterized the
mutant enzyme. The enzyme was also inhibited by BH, showing a 2-fold-higher IC50
value (92.8 4.5 M). However, overall the kinetic properties were not signiﬁcantly
different from the wild-type enzyme (Fig. S3). This suggests that the Cys residue at
position 131 is somehow involved in the binding of BH, despite its location in a region
of the enzyme far from the binding site of other CepI inhibitors (39). Using qPCR, we
investigated the expression of cepI (BCAM1870) and two QS-regulated genes (aidA
[BCAS0293] and zmpA [BCAS0409]) (38) in cultures derived from the TOB-exposed
bioﬁlm of lineage 2. In stationary phase, the expression levels of these genes were not
altered, but lower expression levels for these genes were observed in late log-phase
cultures of the cepI mutant, with remarkably low levels of aidA expression (approxi-
mately 60-fold-lower expression compared to the control) (Fig. 3). This conﬁrms that QS
is indeed affected in this mutant. How the mutation in cepI contributes to an increased
ﬁtness of the evolved B. cenocepacia populations is currently unknown.
Phenotypic characterization of evolved lines. The lack of mutations in known
TOB resistance genes suggested that the overall gradual decrease in susceptibility of B.
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cenocepacia J2315 bioﬁlm cells treated with TOB alone is not caused by a resistance
mechanism speciﬁc for TOB. This is in line with the MIC and MBC values for TOB
obtained for the different lineages (Table 2): in the presence or absence of BH, the MIC
and MBC values for TOB in the evolved lines are equal to or within one 2-fold dilution
of the values obtained for the start culture.
Second, we determined whether the evolutionary changes affected the number of
persister cells in treated cultures (experiments concerning persisters were carried out in
2-fold with lineage 3 only). Persisters are known to occur in B. cenocepacia bioﬁlms (40),
and mutations leading to an increased fraction of persisters could (at least partially)
explain the reduced effect of TOBBH in the evolved lineages. However, the fraction of
persisters recovered from B. cenocepacia J2315 bioﬁlms after exposure to 4 MIC TOB
were low and very similar for the control (0.0224%), the culture evolved in the presence
of TOB (0.0393%), and the culture evolved in the presence of TOBBH (0.0548%), ruling
out increased persister formation as a source for the diminishing effect of TOBBH
(Fig. S4).
The evolved lines, including the untreated control, showed a marginally higher
growth rate in the initial growth phases compared to untreated controls from cycle 1
(Fig. S5). All lines grew largely to the same ﬁnal optical density, although the TOBBH-
treated lineage 2 always had the lowest optical density compared to the other lines
FIG 3 Expression of cepI, aidA, and zmpA in TOB-exposed evolved lineage compared to the control
lineage, as determined by qPCR. Data shown are the fold change in the TOB-exposed lineage compared
to the control. In late log phase, expression of cepI (P  0.05) and aidA (P  0.01) is signiﬁcantly lower
in the TOB-exposed lineage.
TABLE 2MIC and MBC of TOB in B. cenocepacia J2315 recovered from different samplesa
Sample Treatment
MIC of TOB
(g/ml)
MBC of TOB
(g/ml)
Start culture TOB 256 256
TOBBH 256 256
Lineage 1, treated with TOB TOB 128 128
TOBBH 128 128
Lineage 1, treated with TOBBH TOB 256 256
TOBBH 128 256
Lineage 2, treated with TOB TOB 128 128
TOBBH 128 128
Lineage 2, treated with TOBBH TOB 128 128
TOBBH 128 128
Lineage 3, treated with TOB TOB 256 256
TOBBH 256 256
Lineage 3, treated with TOBBH TOB 256 512
TOBBH 512 512
aMIC and MBC were determined in presence (TOBBH) or absence (TOB) of BH.
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(Fig. S5). Interestingly, this is also the only lineage that has mutations in two condi-
tionally essential genes (BCAL2631 and BCAM0965) (33), potentially explaining this
growth phenotype. This suggests that the regrowth phase could be an evolutionary
driving force, in addition to antibiotic treatment, and mutations leading to faster
growth in initial phases would be expected to be present in all evolved lineages. This
is indeed the case, e.g., mutations affecting the pilus assembly protein BCAL1525
possibly accelerate growth in the surrounding growth medium by allowing the cells to
stay in the more oxygenated planktonic phase instead of attaching to the surface of the
bead at the bottom of the wells. In addition, the partial deletions of genomic islands
would decrease genome size and could increase the replication rate. However, the
number of cells on the beads of untreated control lineages remained unchanged
during the experiment, showing that these mutations did not affect bioﬁlm formation.
The regrowth phase is possibly responsible for the lack of mutations leading to
tobramycin resistance and for the lack of mutations in antibiotic targets or mutations,
which could lead to increased expression of canonical resistance genes, such as efﬂux
pumps. Mutations that lead to increased resistance are generally associated with a
decreased ﬁtness of the mutant (36, 41, 42), and individual cells with such mutations
would have been outcompeted during regrowth. However, the decreased growth of
the TOBBH-treated lineage 2 shows that growth characteristics were not the only
evolutionary driving force in this experiment, and the nature of the mutations present
only in treated lineages shows that treatment of the beads did have a speciﬁc impact.
Subsequently, we investigated whether there were differences in production of
reactive oxygen species (ROS) between the start culture and the evolved populations.
We have previously shown that bactericidal antibiotics (including TOB) induce ROS in
B. cenocepacia bioﬁlms and that this contributes to the antibiotic-mediated killing in B.
cenocepacia (40, 43, 44). In addition, we have previously shown that BH increases
TOB-induced oxidative stress in a QS-independent way (27). ROS are an inevitable
by-product of aerobic respiration and, as we observed mutations in genes involved in
oxaloacetate production (BCAL2631 and BCAM0695) or glucose/mannose transport
(BCAL3040) in all lineages treated with TOBBH (but not in lineages treated with TOB
alone or in control lineages; Table 1), we hypothesized these mutations could affect
ROS levels. First, we investigated if basal ROS levels (i.e., ROS levels observed in the
absence of a treatment with a bactericidal antibiotic) were different between the start
culture and the evolved populations. For the control populations and populations
treated with TOB, signiﬁcantly increased basal ROS levels were observed in two and one
of the lineages, respectively (Fig. 4, top panel). For two of the populations that evolved
in the presence of TOBBH, a signiﬁcant decrease in basal ROS production was
observed (P  0.05) (Fig. 4, top panel). These were also the populations in which
mutations in BCAL2631 and/or BCAM0965 (thought to coregulate TCA activity) were
observed. When ROS levels were determined after exposure to TOB, increased ROS
production was observed for one of the control populations while no signiﬁcant
difference was observed for any of the populations evolved in the presence of TOB
alone (P  0.05) (Fig. 4, bottom panel). All populations evolved in the presence of
TOBBH showed reduced ROS levels compared to the start culture after treatment with
TOB; this difference was signiﬁcant (P  0.05) for two lineages (Fig. 4, bottom panel).
Homologues of the putative ABC transporter BCAL0296, mutated in most evolved
treated populations (but not in the controls), have been characterized in other bacteria.
In Bradyrhizobium sp. the transporter homologue BclA is involved in protection against
stress by antimicrobial peptides (45). BclA has multidrug transport activity and is
involved in uptake of peptide-derived/peptide-like compounds, including bleomycin
(46). The homologue in Mycobacterium tuberculosis is involved in uptake of vitamin B12
and bleomycin (47). It is therefore possible that BCAL0296 can import TOB into the
cytoplasm under the experimental conditions used. To investigate this, we used a ﬂow
cytometry based assay to determine uptake of BODIPY-conjugated TOB. While there are
no statistically signiﬁcant differences when all nine groups (three lineages, three
treatments) are compared (Fig. S6), differences in TOB uptake become apparent
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between treatments when data for the three treatments are averaged over the different
lineages (Fig. 5), with TOB uptake signiﬁcantly higher in the evolved control lines than
in the evolved lines exposed to TOB (P  0.045) or TOBBH (P  0.001). No signiﬁcant
difference was observed between the TOB and the TOBBH exposed cultures. The
results from this assay show that there is a signiﬁcantly higher fraction of the popula-
tion positive for BODIPY-TOB in evolved cultures without a mutation in BCAL0296 (i.e.,
the controls) than in evolved cultures with a mutation in BCAL0296 (i.e., the ones
exposed to TOB or TOBBH) (Fig. 5). These data suggest that BCAL0296 is involved in
TOB import in B. cenocepacia and that the mutations occurring after repeated exposure
to TOB or TOBBH contribute to the reduced antimicrobial activity of TOB observed.
Conclusion. In the present study, we demonstrate that during experimental evo-
lution in vitro, B. cenocepacia J2315 bioﬁlms gradually become less susceptible to TOB
and TOBBH. Mutations in genes belonging to different functional categories were
FIG 4 (Top) Basal ROS levels in evolved populations (relative compared to the start culture). (Bottom)
ROS levels in evolved populations after exposure to 4 the MIC TOB (relative compared to start culture).
The data shown are averages, and error bars represent standard errors (n 3 5). Statistically signiﬁcant
differences (P  0.05) are indicated by an asterisk.
FIG 5 Differences in TOB uptake between treatments (based on averaged data over the different
lineages). The data shown are averages, and error bars indicate standard errors (n 24). TOB uptake is
signiﬁcantly lower in lineages exposed to TOB (P  0.045) and TOBBH (P  0.001).
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observed in the evolved populations exposed to the combination of TOB and BH, and
some point to modiﬁcations in metabolism as a mechanism underlying the reduced
susceptibility. The reduced levels of ROS (both basal levels and levels induced after
exposure to TOB) observed in the lineages treated with TOBBH point in the same
direction. In addition, most lineages exposed to TOB or TOBBH had mutations in
BCAL0296, encoding an ABC transporter. Cells from populations in which BCAL0296
was mutated were more likely to accumulate lower levels of TOB intracellularly,
providing an additional explanation for the reduced susceptibility of these evolved
lineages. Although some genetic changes were found in multiple evolved populations,
different lineages exposed to the same treatment appeared to have used different
evolutionary trajectories to counteract the potentiating activity of BH. Our results
indicate that loss of susceptibility to potentiators can develop in multiple ways, and this
might limit their clinical applicability. Finally, our data demonstrate that experimental
evolution combined with high-throughput sequencing can indeed identify the genetic
changes behind reduced susceptibility and allows the identiﬁcation of hitherto-
unknown genes of interest likely involved in B. cenocepacia bioﬁlm resistance and
tolerance (48).
MATERIALS AND METHODS
Strains and culture conditions. B. cenocepacia J2315 (LMG 16656) was stored at –80°C using
Microbank vials (Prolab Diagnostics, Richmond Hill, Ontario, Canada) and subcultured at 37°C on
tryptone soy agar (TSA; Lab M, Lancashire, United Kingdom). Overnight cultures were grown aerobically
in Mueller-Hinton broth (MHB; Lab M) at 37°C.
Reagents. Tobramycin (TOB; TCI Europe, Zwijndrecht, Belgium) was dissolved in physiological saline
(PS; 0.9% [wt/vol] NaCl; Applichem, Darmstadt, Germany), ﬁlter sterilized (0.22 m; Whatman, Dassel,
Germany), and stored at 4°C until use. Stock solutions of BH (Sigma-Aldrich, Bornem, Belgium) were
prepared in dimethyl sulfoxide (DMSO; Sigma-Aldrich) and diluted in PS prior to use.
Bioﬁlm formation on beads. The set-up for bioﬁlm formation was inspired by that reported by
Traverse et al. (26). Cryobeads from Microbank vials (Prolab Diagnostics) were used as the substrates for
bioﬁlm formation. The beads were rinsed with PS prior to use to remove the cryopreservative present in
the Microbank vials. This was achieved by adding 1 ml of PS, vortexing the vial, removing the PS, and
repeating this three times. Six beads were then transferred to the wells of a 24-well microtiter plate (MTP;
SPL Lifescience, South Korea), and 1 ml of a diluted overnight culture of B. cenocepacia J2315 (containing
approximately 5 107 CFU per ml of MHB) was used as inoculum. The MTP was statically incubated at
37°C for 24 h. To evaluate the ability of B. cenocepacia J2315 cells to form mature bioﬁlms on the beads,
Live/Dead staining (Live/Dead BacLight bacterial viability kit; Thermo Fisher Scientiﬁc, Invitrogen, Carls-
bad, CA) was performed after 24 h of bioﬁlm formation. The bioﬁlms on the beads were visualized using
an EVOS FL Auto cell imaging system (Thermo Fisher Scientiﬁc, Waltham, MA; Syto9, ex  470/22 nm
and em  510/42 nm; propidium iodide, ex  531/40 nm and em  593/40 nm).
Evolution experiment. To evaluate the inﬂuence of repeated treatments on bioﬁlm susceptibility,
cells were exposed to 15 cycles of bioﬁlm formation (24 h), treatment (24 h), and planktonic regrowth
(48 h) (Fig. 1). The planktonic regrowth step was included to generate a sufﬁciently high number of cells
to set up a new bioﬁlm for the next cycle. Bioﬁlms were treated with PS (untreated control), TOB alone
(at a concentration of 768 g/ml, which equals 3 the MIC), and TOB in combination with BH (250 M).
The concentration of TOB and BH was selected based on preliminary experiments: the concentrations
used in the present study lead to a signiﬁcant reduction in cell numbers compared to the untreated
control, but not complete eradication, so that regrowth in the following cycles can occur. Three
independent experiments (designated as lineages) were set up for each condition, i.e., TOB (tobramycin),
TOBBH, and an untreated control. The three lineages were started from three different overnight start
cultures. Bioﬁlms were grown as described above, and after 24 h the beads were rinsed with PS and
treated with TOB or a combination of TOBBH. After 24 h of treatment at 37°C, the supernatant was
removed, and the beads were rinsed with PS. Each well contained six beads: two beads were transferred
to Eppendorf tubes containing 8% DMSO (Sigma-Aldrich) in MH for storage at –80°C, while the four
remaining beads were transferred to a Falcon tube containing 8 ml of MH medium. Sessile cells were
detached from the beads by three cycles of vortexing (1 min, Vortex-Genie 2; Scientiﬁc Industries, Inc.,
Bohemia, NY) and sonication (1 min; Branson 3510; Branson Ultrasonics Corp., Danbury, CT). Then, 6 ml
of this bacterial suspension was transferred to another tube, followed by incubation for 48 h for
regrowth, while shaking at 250 rpm at 37°C (KS 4000i control; IKA Works, Wilmington, NC). The remaining
2 ml was used to determine the number of surviving cells per bead (CFU/bead) by plating.
Determination of the MIC and MBC. To verify whether possible changes in susceptibility over time
were due to increased resistance toward TOB, the MIC and MBC for TOB were determined for the start
and end populations. MICs were determined according to the EUCAST broth microdilution assay using
ﬂat-bottom 96-well MTPs (SPL Lifescience) (49). The MIC was deﬁned as the lowest concentration with
a similar optical density as uninoculated growth medium. Absorbance was measured at 590 nm with a
multilabel MTP reader (EnVision; Perkin-Elmer LAS, Waltham, MA). All MIC determinations were per-
formed in duplicate. The MBC was determined by plating the suspension used for the MIC test, and the
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MBC was the lowest concentration that did not allow recovery of colonies after 48 h of incubation at
37°C.
Determination of the number of persisters in tobramycin-exposed B. cenocepacia J2315
bioﬁlms. To determine whether the evolutionary changes affected persistence, the number of persisters
surviving TOB treatment was compared between bioﬁlms formed by the start and evolved cultures.
Bioﬁlms were grown in 96-well microtiter plates as described previously (50) and exposed for 24 h to TOB
in a concentration of 4 the MIC (1,024 g/ml) (40). Brieﬂy, an inoculum suspension containing 5 107
CFU/ml was added to the wells of a round bottomed 96-well microtiter plate. After 4 h of adhesion, the
supernatant was removed, and the plates were rinsed with PS. Subsequently, 100 l of fresh MHB was
added, and the plates were further incubated at 37°C. After 24 h, the supernatant was removed and
120 l of a TOB solution in PS or 120 l of PS (i.e., control) was added. After 24 h, the cells were harvested
by vortexing and sonication (2 5 min; Branson 3510) and quantiﬁed by plating on Luria-Bertani agar.
Ten wells were included per strain, and the experiment was repeated twice (n 3).
Measurement of ROS levels. To investigate whether there were differences in the production of
ROS between the start culture and the evolved lineages, ROS were measured in treated and
untreated start and evolved cultures. To measure ROS planktonic cultures were exposed to 2=,7=-
dichlorodihydroﬂuorescein diacetate (H2DCFDA) in a ﬁnal concentration of 10 M in Luria-Bertani broth
(43). After 45 min of incubation protected from light, the cells were washed with phosphate-buffered
saline (PBS) and treated with TOB in a concentration of 4 the MIC or pH-matched PBS (i.e., the
untreated control solution with the same pH as the antibiotic solution) for 24 h. Fluorescence (
excitation  485 nm,  emission  535 nm) was measured using an Envision plate reader. The
autoﬂuorescence of bacterial cells incubated without the probe and background ﬂuorescence of the
buffer solutions was measured and taken into account when calculating the net ﬂuorescence. For
the planktonic cultures, an overnight culture was diluted to an optical density of 0.1 (approximately 108
cells/ml). After an additional 24 h of growth in a shaking warm water bath, cell suspensions at an optical
density of 1 (approximately 109 cells/ml) were transferred to falcon tubes and centrifuged for 9 min at
a 3,634 relative centrifugal force. Cells were resuspended in fresh medium with or without dye to
measure ROS. Five wells were included per condition and the experiment was repeated twice (n 3 5).
Genome sequencing and data analysis. After planktonic regrowth of the cells, DNA was extracted
using a modiﬁed bead-beater protocol, adapted from Mahenthiralingam et al. (51). RNase-treated DNA
was then quantiﬁed using the BioDrop LITE (BioDrop, Cambridge, UK). Genomic DNA from the start
culture and all evolved cultures obtained after 15 cycles were sequenced. Libraries were prepared using
the NEBNext kit from Illumina and sequenced either on an Illumina Nextseq 500 or on a HiSeq 4000,
generating 150-bp paired-end reads (Table S3). The experimental protocols and the raw sequencing data
of all samples can be found in ArrayExpress under accession number E-MTAB-6236. Sequenced reads
were quality trimmed (error probability limit, 0.05) and mapped to the B. cenocepacia J2315 reference
genome (34) using CLC Genomics Workbench version 11.0.1. (Qiagen, Aarhus, Denmark) with a cutoff
80% for similarity and a 50%mapped read length. The mapping parameters were as follows: match score,
1; mismatch cost, 2; insertion and deletion cost, 3. More than 98.6% of reads mapped to the reference
genome for all samples (Table S3). The unmapped reads were de novo assembled in CLC Genomics
Workbench, but no contigs with a coverage 10% of the average coverage of the respective sample
were found, and gene acquisition was therefore excluded. In CLC Genomics Workbench, the InDels and
Structural Variants tool was used to detect insertions and deletions, with a P value threshold of 0.0001.
The output was manually screened on mapping patterns of unaligned read ends, and only entries with
a single breakpoint and identical sequences in the unaligned read ends were reported. The consensus
sequence of the unaligned read ends was then used to conﬁrm the deletion or to identify the nature of
the inserted sequence. A larger insertion sequence cannot be fully deduced in this manner, but only a
certain type of transposase which was already present multiple times in the B. cenocepacia J2315
reference genome was detected: Burkholderia cepacia insertion element IS407. Both consensus se-
quences at insertion breakpoints were consistent with either end of this transposase, it was therefore
concluded that the insertion consisted of only that transposase. The Basic Variant Detection tool was
used to detect SNPs with a minimum coverage of 10 and a reference-to-variant ratio of 35%. This was
the lowest cutoff that allowed us to clearly distinguish true SNPs from sequencing errors. All SNPs were
then manually screened for false positives in regions containing repetitive sequences or hairpins, which
caused poor mapping. The function of the genes that acquired mutational changes was determined
using the Conserved Domain database (52) and Burkholderia Genome Database (53).
qPCR. Cultures from cycle 15, control lineage 3, and Tob lineage 2 were cultivated in MHB in a
shaking incubator at 150 rpm for 6 to 10 h. Late-log-phase cultures were harvested at a density of 1 109
to 1.3 109 CFU/ml, and stationary-phase cultures were harvested at a density of 3 109 to 4.5 109
CFU/ml. Cell pellets were frozen at –80°C, and RNA was extracted within 1 week of harvest using a
RiboPure bacteria kit (Thermo Fisher, Rochester, NY) according to the standard protocol, including DNase
treatment. RNA was quantiﬁed with the BioDrop LITE. cDNA was generated with a high-capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City, CA) from 500 ng of RNA. qPCR was performed
in a CFX96 Real-Time System C1000 thermal cycler (Bio-Rad, Hercules, CA) using GoTaq qPCR Master Mix
(Promega, Madison, WI). Cq values were normalized against a previously validated control gene (rpoD,
BCAM0918) (54, 55). Fold changes were calculated compared to a standard (mix of all cDNAs in
experiment) and log transformed. The primers are listed in Table S4.
Growth curves. Growth curves were determined in MHB. Portions (200 l/well) of a 5 105 CFU/ml
inoculum were added in triplicates to round-bottom MTPs, and the absorbance at 590 nm was measured
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in a microplate reader (Envision; Perkin-Elmer, Shelton, CT), every 30 min for 50 h. The experiment was
repeated three times, and representative curves are shown.
Determination of CepI activity in the presence of BH. B. cenocepacia CepI was expressed in
Escherichia coli BL21(DE3) cells and puriﬁed according to a previously described procedure (56). The
enzymatic activity was determined by a spectrophotometric assay according to Christensen et al. (57),
which measures the holo-ACP formation by titrating the release of the free thiol of ACP with dichloro-
phenylindophenol (DCPIP;   19,100 M1 cm1). Measurements were performed at 37°C, in a ﬁnal
volume of 100 l, using an Eppendorf Biospectrometer. The standard reaction mixture contained 50 mM
HEPES (pH 7.5), 0.005% Nonidet P-40, 0.13 mM DCPIP, 70 M octanoyl-ACP (C8-ACP) (58, 59), and 4 M
CepI; the reactions were started by the addition of 40 M S-adenosylmethionine (SAM) after preincu-
bation for 10 min. CepI inhibition was initially screened at 200 M BH (dissolved in DMSO). CepI
inhibition was initially screened at 200 M (dissolved in DMSO), and the IC50 was then determined by
measuring the enzyme activities in the presence of different BH concentrations, and ﬁtting data
according to equation 1:
A[I] A[0] 10 [I][I] IC50 (1)
where A[I] is the enzyme activity at BH concentration [I] and A[0] is the enzyme activity without BH. All
measurements were performed in triplicate.
Site-directed mutagenesis of cepI. Plasmid pETSUMO-CepI (56) was used as the template for
PCR mutagenesis experiment to generate the amino acid substitution C131W, using the primers
CepC131Wfor (5=-GGCCGTCGTCGAATGGGCGGCCCAGCTCGGG-3=) and CepC131Wrev (5=-CCCGAGCTGG
GCCGCCCATTCGACGACGGCC-3=). The site-directed mutagenesis was carried out as previously described
(60) using HotStar HiFidelity Polymerase (Qiagen) and FastDigest DpnI (Thermo Fisher Scientiﬁc). The
mutated CepIC131W was expressed and puriﬁed as described above for the wild-type protein.
Quantiﬁcation of intracellular tobramycin levels. BODIPY-labeled tobramycin was synthesized as
previously described (61). Bacteria were grown under bioﬁlm-forming conditions for 4 h in MHB in the
presence of 0.75 g/ml BODIPY-tobramycin at 37°C. After 4 h of bioﬁlm formation, the bioﬁlm was rinsed
to remove extracellular tobramycin, homogenized and subjected to ﬂow cytometry analysis (Attune NxT;
Life Technologies). The bacterial population was delineated based on the forward and side scatter
signals, and a threshold was set to exclude noncellular particles and cell debris. BODIPY-tobramycin that
associated with bacterial cells was determined through excitation with a 488-nm laser. Fluorescence
emission was detected through a 530/30 bandpass ﬁlter. Controls included bacterial bioﬁlm cells that
were not exposed to BODIPY-tobramycin (negative control) or to incremental levels of tobramycin to
determine the concentration at which saturation was obtained. Based on the negative control and the
concentration of tobramycin where maximal population saturation was obtained, negative and positive
ﬂow cytometry gates, respectively, were determined. At least 10,000 bacteria were analyzed per sample.
Statistical analysis. To determine whether the observed variations in survival over time for the
different treatments were statistically signiﬁcant, a linear mixed-effect model (LMEM) was used. The
model uses the log(CFU/bead) as the dependent variable and cycle, treatment, lineage, and their two-
and three-way interactions as ﬁxed effects and was ﬁt using SAS version 9.4 (SAS Institute, Cary, NC). To
account for possible correlations between the measurements over cycles, a compound symmetry
variance covariance structure was used. All interaction effects that were not signiﬁcant were excluded
from the model. When an interaction was signiﬁcant, this was considered the ﬁxed effect to evaluate
differences in treatment effect. Per lineage, treatments were compared pairwise to TOB treatment using
the Tukey adjustment method. Assumptions associated with the LMEM were checked based on residuals
from the ﬁtted ﬁnal model (Table S2).
Other data sets were analyzed using SPSS version 25 software (SPSS, Chicago, IL). The Shapiro-Wilk
test was used to verify the normal distribution assumption of the data. Differences between the means
of normally and not-normally distributed data were assessed using one-way analysis of variance testing
or a Kruskal-Wallis nonparametric test, respectively, followed by a Dunnett’s post hoc analysis. P values
smaller than 0.05 were considered statistically signiﬁcant.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.02092-18.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.8 MB.
ACKNOWLEDGMENTS
This study was supported by the Special Research Fund of Ghent University (grant
BOF13/24j/017); the Belgian Science Policy Ofﬁce (grant P7/28 of the Interuniversity
Attraction Pole program); the Fund for Scientiﬁc Research (postdoctoral fellowship to
HVA and Odysseus fellowship to A.C.); and the Italian Ministry of Education, University
and Research (MIUR; Dipartimenti di Eccellenza Program 2018–2022, Department of
Biology and Biotechnology L. Spallanzani, University of Pavia) (to L.R.C. and S.B.). The
funders had no role in study design, data collection and interpretation, or the decision
to submit the work for publication.
Sass et al. Antimicrobial Agents and Chemotherapy
April 2019 Volume 63 Issue 4 e02092-18 aac.asm.org 12
 o
n
 M
arch 28, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
REFERENCES
1. Gill EE, Franco OL, Hancock RE. 2015. Antibiotic adjuvants: diverse
strategies for controlling drug-resistant pathogens. Chem Biol Drug Des
85:56–78. https://doi.org/10.1111/cbdd.12478.
2. Bernal P, Molina-Santiago C, Daddaoua A, Llamas MA. 2013. Antibiotic
adjuvants: identiﬁcation and clinical use. Microb Biotechnol 6:445–449.
https://doi.org/10.1111/1751-7915.12044.
3. Brown D. 2015. Antibiotic resistance breakers: can repurposed drugs ﬁll
the antibiotic discovery void? Nat Rev Drug Discov 14:821–832. https://
doi.org/10.1038/nrd4675.
4. Brown ED, Wright GD. 2016. Antibacterial drug discovery in the resis-
tance era. Nature 529:336–343. https://doi.org/10.1038/nature17042.
5. Wright GD. 2016. Antibiotic adjuvants: rescuing antibiotics from resis-
tance. Trends Microbiol 24:862–871. https://doi.org/10.1016/j.tim.2016
.06.009.
6. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. 2011. Quorum sensing
inhibitors increase the susceptibility of bacterial bioﬁlms to antibiotics in
vitro and in vivo. Antimicrob Agents Chemother 55:2655–2661. https://
doi.org/10.1128/AAC.00045-11.
7. Waters CM, Bassler BL. 2005. Quorum sensing: cell-to-cell communica-
tion in bacteria. Annu Rev Cell Dev Biol 21:319–346. https://doi.org/10
.1146/annurev.cellbio.21.012704.131001.
8. Defoirdt T, Boon N, Bossier P. 2010. Can bacteria evolve resistance to
quorum sensing disruption? PLoS Pathog 6:e1000989. https://doi.org/
10.1371/journal.ppat.1000989.
9. Melander RJ, Melander C. 2017. The challenge of overcoming antibiotic
resistance: an adjuvant approach? ACS Infect Dis 3:559–563. https://doi
.org/10.1021/acsinfecdis.7b00071.
10. Hirakawa H, Tomita H. 2013. Interference of bacterial cell-to-cell
communication: a new concept of antimicrobial chemotherapy breaks
antibiotic resistance. Front Microbiol 4:114. https://doi.org/10.3389/
fmicb.2013.00114.
11. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N,
Schembri MA, Song Z, Kristoffersen P, Maneﬁeld M, Costerton JW, Molin S,
Eberl L, Steinberg P, Kjelleberg S, Hoiby N, Givskov M. 2003. Attenuation of
Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J
22:3803–3815. https://doi.org/10.1093/emboj/cdg366.
12. Gerdt JP, Blackwell HE. 2014. Competition studies conﬁrm two major
barriers that can preclude the spread of resistance to quorum-sensing
inhibitors in bacteria. ACS Chem Biol 9:2291–2299. https://doi.org/10
.1021/cb5004288.
13. Mellbye B, Schuster M. 2011. The sociomicrobiology of antivirulence
drug resistance: a proof of concept. mBio 2:e00131-11.
14. Maeda T, García-Contreras R, Pu M, Sheng L, Garcia LR, Tomás M, Wood
TK. 2012. Quorum quenching quandary: resistance to antivirulence com-
pounds. ISME J 6:493–501. https://doi.org/10.1038/ismej.2011.122.
15. Heurlier K, Denervaud V, Haenni M, Guy L, Krishnapillai V, Haas D. 2005.
Quorum-sensing-negative (lasR) mutants of Pseudomonas aeruginosa
avoid cell lysis and death. J Bacteriol 187:4875–4883. https://doi.org/10
.1128/JB.187.14.4875-4883.2005.
16. Tomas M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore
DM, Woodford N. 2010. Efﬂux pumps, OprD porin, AmpC beta-
lactamase, and multiresistance in Pseudomonas aeruginosa isolates from
cystic ﬁbrosis patients. Antimicrob Agents Chemother 54:2219–2224.
https://doi.org/10.1128/AAC.00816-09.
17. Garcia-Contreras R, Maeda T, Wood TK. 2016. Can resistance against
quorum-sensing interference be selected? ISME J 10:4–10. https://doi
.org/10.1038/ismej.2015.84.
18. Steenackers HP, Parijs I, Dubey A, Foster KR, Vanderleyden J. 2016.
Experimental evolution in bioﬁlm populations. FEMS Microbiol Rev 40:
373–397. https://doi.org/10.1093/femsre/fuw002.
19. Van den Bergh B, Swings T, Fauvart M, Michiels J. 2018. Experimental
design, population dynamics, and diversity in microbial experimental
evolution. Microbiol Mol Biol Rev 82. https://doi.org/10.1128/MMBR
.00008-18.
20. Zhang Q, Lambert G, Liao D, Kim H, Robin K, Tung CK, Pourmand N,
Austin RH. 2011. Acceleration of emergence of bacterial antibiotic resis-
tance in connected microenvironments. Science (New York, NY) 333:
1764–1767. https://doi.org/10.1126/science.1208747.
21. Van Acker H, Van Dijck P, Coenye T. 2014. Molecular mechanisms of
antimicrobial tolerance and resistance in bacterial and fungal bioﬁlms.
Trends Microbiol 22:326–333. https://doi.org/10.1016/j.tim.2014.02.001.
22. Mahenthiralingam E, Urban TA, Goldberg JB. 2005. The multifarious,
multireplicon Burkholderia cepacia complex. Nat Rev Microbiol
3:144–156. https://doi.org/10.1038/nrmicro1085.
23. Coenye T. 2010. Social interactions in the Burkholderia cepacia complex:
bioﬁlms and quorum sensing. Future Microbiol 5:1087–1099. https://doi
.org/10.2217/fmb.10.68.
24. Scoffone VC, Chiarelli LR, Trespidi G, Mentasti M, Riccardi G, Buroni S.
2017. Burkholderia cenocepacia infections in cystic ﬁbrosis patients: drug
resistance and therapeutic approaches. Front Microbiol 8:1592. https://
doi.org/10.3389/fmicb.2017.01592.
25. Luo J, Dong B, Wang K, Cai S, Liu T, Cheng X, Lei D, Chen Y, Li Y, Kong
J, Chen Y. 2017. Baicalin inhibits bioﬁlm formation, attenuates the
quorum sensing-controlled virulence and enhances Pseudomonas
aeruginosa clearance in a mouse peritoneal implant infection model.
PLoS One 12:e0176883. https://doi.org/10.1371/journal.pone.0176883.
26. Traverse CC, Mayo-Smith LM, Poltak SR, Cooper VS. 2013. Tangled bank
of experimentally evolved Burkholderia bioﬁlms reﬂects selection during
chronic infections. Proc Natl Acad Sci U S A 110:E250–E259. https://doi
.org/10.1073/pnas.1207025110.
27. Slachmuylders L, Van Acker H, Brackman G, Sass A, Van Nieuwerburgh F,
Coenye T. 2018. Elucidation of the mechanism behind the potentiating
activity of baicalin against Burkholderia cenocepacia bioﬁlms. PLoS One
13:e0190533. https://doi.org/10.1371/journal.pone.0190533.
28. Sass AM, Van Acker H, Forstner KU, Van Nieuwerburgh F, Deforce D,
Vogel J, Coenye T. 2015. Genome-wide transcription start site proﬁling in
bioﬁlm-grown Burkholderia cenocepacia J2315. BMC Genomics 16:775.
https://doi.org/10.1186/s12864-015-1993-3.
29. Roux N, Spagnolo J, de Bentzmann S. 2012. Neglected but amazingly
diverse type IVb pili. Res Microbiol 163:659–673. https://doi.org/10
.1016/j.resmic.2012.10.015.
30. Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-Jorgensen A, Molin
S, Tolker-Nielsen T. 2003. Bioﬁlm formation by Pseudomonas aeruginosa
wild type, ﬂagella and type IV pili mutants. Mol Microbiol 48:1511–1524.
https://doi.org/10.1046/j.1365-2958.2003.03525.x.
31. Davies EV, James CE, Brockhurst MA, Winstanley C. 2017. Evolutionary
diversiﬁcation of Pseudomonas aeruginosa in an artiﬁcial sputum model.
BMC Microbiol 17:3. https://doi.org/10.1186/s12866-016-0916-z.
32. Sauer U, Eikmanns BJ. 2005. The PEP-pyruvate-oxaloacetate node as the
switch point for carbon ﬂux distribution in bacteria. FEMS Microbiol Rev
29:765–794. https://doi.org/10.1016/j.femsre.2004.11.002.
33. Wong YC, Abd El Ghany M, Naeem R, Lee KW, Tan YC, Pain A, Nathan S.
2016. Candidate essential genes in Burkholderia cenocepacia J2315 iden-
tiﬁed by genome-wide TraDIS. Front Microbiol 7:1288. https://doi.org/
10.3389/fmicb.2016.01288.
34. Holden MT, Seth-Smith HM, Crossman LC, Sebaihia M, Bentley SD,
Cerdeno-Tarraga AM, Thomson NR, Bason N, Quail MA, Sharp S,
Cherevach I, Churcher C, Goodhead I, Hauser H, Holroyd N, Mungall K,
Scott P, Walker D, White B, Rose H, Iversen P, Mil-Homens D, Rocha EP,
Fialho AM, Baldwin A, Dowson C, Barrell BG, Govan JR, Vandamme P,
Hart CA, Mahenthiralingam E, Parkhill J. 2009. The genome of Burkhold-
eria cenocepacia J2315, an epidemic pathogen of cystic ﬁbrosis patients.
J Bacteriol 191:261–277. https://doi.org/10.1128/JB.01230-08.
35. Garneau-Tsodikova S, Labby KJ. 2016. Mechanisms of resistance to
aminoglycoside antibiotics: overview and perspectives. MedChem-
Comm 7:11–27. https://doi.org/10.1039/C5MD00344J.
36. Hughes D, Andersson DI. 2017. Evolutionary trajectories to antibiotic
resistance. Annu Rev Microbiol 71:579–596. https://doi.org/10.1146/
annurev-micro-090816-093813.
37. Sokol PA, Sajjan U, Visser MB, Gingues S, Forstner J, Kooi C. 2003. The
CepIR quorum-sensing system contributes to the virulence of Burkhold-
eria cenocepacia respiratory infections. Microbiology (Reading, England)
149:3649–3658. https://doi.org/10.1099/mic.0.26540-0.
38. Subsin B, Chambers CE, Visser MB, Sokol PA. 2007. Identiﬁcation of genes
regulated by the cepIR quorum-sensing system in Burkholderia cenoce-
pacia by high-throughput screening of a random promoter library. J
Bacteriol 189:968–979. https://doi.org/10.1128/JB.01201-06.
39. Buroni S, Scoffone VC, Fumagalli M, Makarov V, Cagnone M, Trespidi G,
De Rossi E, Forneris F, Riccardi G, Chiarelli LR. 2018. Investigating the
mechanism of action of diketopiperazines inhibitors of the Burkholderia
cenocepacia quorum sensing synthase CepI: a site-directed mutagenesis
study. Front Pharmacol 9:836. https://doi.org/10.3389/fphar.2018.00836.
Susceptibility to a Potentiator in B. cenocepacia Antimicrobial Agents and Chemotherapy
April 2019 Volume 63 Issue 4 e02092-18 aac.asm.org 13
 o
n
 M
arch 28, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
40. Van Acker H, Sass A, Bazzini S, De Roy K, Udine C, Messiaen T, Riccardi G,
Boon N, Nelis HJ, Mahenthiralingam E, Coenye T. 2013. Bioﬁlm-grown
Burkholderia cepacia complex cells survive antibiotic treatment by avoid-
ing production of reactive oxygen species. PLoS One 8:e58943. https://
doi.org/10.1371/journal.pone.0058943.
41. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it
possible to reverse resistance? Nat Rev Microbiol 8:260–271. https://doi
.org/10.1038/nrmicro2319.
42. Durao P, Balbontin R, Gordo I. 2018. Evolutionary mechanisms shaping
the maintenance of antibiotic resistance. Trends Microbiol 26:677–691.
https://doi.org/10.1016/j.tim.2018.01.005.
43. Van Acker H, Gielis J, Acke M, Cools F, Cos P, Coenye T. 2016. The role of
reactive oxygen species in antibiotic-induced cell death in Burkholderia
cepacia complex bacteria. PLoS One 11:e0159837. https://doi.org/10
.1371/journal.pone.0159837.
44. Van Acker H, Coenye T. 2017. The role of reactive oxygen species in
antibiotic-mediated killing of bacteria. Trends Microbiol 25:456–466.
https://doi.org/10.1016/j.tim.2016.12.008.
45. Barriere Q, Guefrachi I, Gully D, Lamouche F, Pierre O, Fardoux J, Chain-
treuil C, Alunni B, Timchenko T, Giraud E, Mergaert P. 2017. Integrated
roles of BclA and DD-carboxypeptidase 1 in Bradyrhizobium differentia-
tion within NCR-producing and NCR-lacking root nodules. Sci Rep
7:9063. https://doi.org/10.1038/s41598-017-08830-0.
46. Guefrachi I, Pierre O, Timchenko T, Alunni B, Barriere Q, Czernic P,
Villaecija-Aguilar JA, Verly C, Bourge M, Fardoux J, Mars M, Kondorosi E,
Giraud E, Mergaert P. 2015. Bradyrhizobium BclA is a peptide transporter
required for bacterial differentiation in symbiosis with Aeschynomene
legumes. Mol Plant Microbe Interact 28:1155–1166. https://doi.org/10
.1094/MPMI-04-15-0094-R.
47. Gopinath K, Venclovas C, Ioerger TR, Sacchettini JC, McKinney JD, Miz-
rahi V, Warner DF. 2013. A vitamin B12 transporter in Mycobacterium
tuberculosis. Open Biol 3:120175. https://doi.org/10.1098/rsob.120175.
48. Cooper VS. 2018. Experimental evolution as a high-throughput screen
for genetic adaptations. mSphere 3:e00121-18. https://doi.org/10.1128/
mSphere.00121-18.
49. ESCMID. 2003. Determination of minimum inhibitory concentrations
(MICs) of antibacterial agents by broth dilution. Clin Microbiol Infect
9:ix–xv. https://doi.org/10.1046/j.1469-0691.2003.00790.x.
50. Van Acker H, Van Snick E, Nelis HJ, Coenye T. 2010. In vitro activity of
temocillin against planktonic and sessile Burkholderia cepacia complex
bacteria. J Cystic Fibrosis 9:450–454. https://doi.org/10.1016/j.jcf.2010
.08.015.
51. Mahenthiralingam E, Campbell ME, Foster J, Lam JS, Speert DP. 1996.
Random ampliﬁed polymorphic DNA typing of Pseudomonas aeruginosa
isolates recovered from patients with cystic ﬁbrosis. J Clin Microbiol
34:1129–1135.
52. Marchler-Bauer A, Bo Y, Han L, He J, Lanczycki CJ, Lu S, Chitsaz F,
Derbyshire MK, Geer RC, Gonzales NR, Gwadz M, Hurwitz DI, Lu F,
Marchler GH, Song JS, Thanki N, Wang Z, Yamashita RA, Zhang D, Zheng
C, Geer LY, Bryant SH. 2017. CDD/SPARCLE: functional classiﬁcation of
proteins via subfamily domain architectures. Nucleic Acids Res 45:
D200–D203. https://doi.org/10.1093/nar/gkw1129.
53. Winsor GL, Khaira B, Van Rossum T, Lo R, Whiteside MD, Brinkman FS.
2008. The Burkholderia Genome Database: facilitating ﬂexible queries
and comparative analyses. Bioinformatics (Oxford, England) 24:
2803–2804. https://doi.org/10.1093/bioinformatics/btn524.
54. Sass AM, Schmerk C, Agnoli K, Norville PJ, Eberl L, Valvano MA, Mahen-
thiralingam E. 2013. The unexpected discovery of a novel low-oxygen-
activated locus for the anoxic persistence of Burkholderia cenocepacia.
ISME J 7:1568–1581. https://doi.org/10.1038/ismej.2013.36.
55. Kiekens S, Sass A, Van Nieuwerburgh F, Deforce D, Coenye T. 2018. The
small RNA ncS35 regulates growth in Burkholderia cenocepacia J2315.
mSphere 3:e00579-17. https://doi.org/10.1128/mSphere.00579-17.
56. Scoffone VC, Chiarelli LR, Makarov V, Brackman G, Israyilova A, Azzalin A,
Forneris F, Riabova O, Savina S, Coenye T, Riccardi G, Buroni S. 2016.
Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia
quorum sensing in vitro and in vivo. Sci Rep 6:32487. https://doi.org/10
.1038/srep32487.
57. Christensen QH, Grove TL, Booker SJ, Greenberg EP. 2013. A high-
throughput screen for quorum-sensing inhibitors that target acyl-
homoserine lactone synthases. Proc Natl Acad Sci U S A 110:
13815–13820. https://doi.org/10.1073/pnas.1313098110.
58. Cronan JE, Thomas J. 2009. Bacterial fatty acid synthesis and its relation-
ships with polyketide synthetic pathways. Methods Enzymol 459:
395–433. https://doi.org/10.1016/S0076-6879(09)04617-5.
59. Quadri LE, Weinreb PH, Lei M, Nakano MM, Zuber P, Walsh CT. 1998.
Characterization of Sfp, a Bacillus subtilis phosphopantetheinyl trans-
ferase for peptidyl carrier protein domains in peptide synthetases. Bio-
chemistry 37:1585–1595. https://doi.org/10.1021/bi9719861.
60. Bachman J. 2013. Site-directed mutagenesis. Methods Enzymol 529:
241–248. https://doi.org/10.1016/B978-0-12-418687-3.00019-7.
61. Messiaen AS. 2013. Towards improvement of antibiotic therapy for
treating Burkholderia cepacia complex bioﬁlm infections in cystic ﬁbro-
sis patients. PhD thesis. Ghent University, Gent, Belgium.
Sass et al. Antimicrobial Agents and Chemotherapy
April 2019 Volume 63 Issue 4 e02092-18 aac.asm.org 14
 o
n
 M
arch 28, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
